Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
Professor: Venerino Poletti
Kommentar til artiklen:
Immune check points are key elements in lung cancer pathogenesis. The expression on tumor cells programmed death ligand 1 (PD-L1) of 50% or greater has been shown to be associated with a significant response to pembrolizumab, an inhibitor of this pathway. In this double-blind, phase 3 trial 616 patients with metastatic nonsquamous NSCLC without sensitizing EGFR or ALK mutations were randomized to receive pemetrexed and a platinum-based drug plus either 200 mg of pembrolizumab or placebo. Improvement in overall survival and progression-free survival was seen across all PD-L1 categories. The use of immune check point inhibitors is appearing as a first line treatment approach in patients with lung nonsquamous NSCLC regardless of the PD-L1 expression.